Candel Therapeutics Inc CADL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CADL is a good fit for your portfolio.
News
-
Candel Therapeutics Shares Leap Premarket on FDA Orphan-Drug Designation
-
Candel Therapeutics stock jumps as pancreatic cancer treatment shows promise
-
Candel Gets FDA Fast-Track Designation for CAN-3110 in Recurrent High-Grade Glioma
-
Candel Therapeutics Shares Soar After FDA Fast Track of CAN-2409
-
Candel Gets FDA Fast-Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
Trading Information
- Previous Close Price
- $6.43
- Day Range
- $6.02–6.60
- 52-Week Range
- $0.66–11.40
- Bid/Ask
- $6.56 / $6.66
- Market Cap
- $187.53 Mil
- Volume/Avg
- 391,978 / 5.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 42
- Website
- https://www.candeltx.com
Valuation
|
Metric
|
CADL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 14.59 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CADL
|
|---|---|
Quick Ratio | 2.50 |
Current Ratio | 2.59 |
Interest Coverage | −14.42 |
Quick Ratio
CADL
Profitability
|
Metric
|
CADL
|
|---|---|
Return on Assets (Normalized) | −59.93% |
Return on Equity (Normalized) | −114.83% |
Return on Invested Capital (Normalized) | −65.03% |
Return on Assets
CADL
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vtnqtwpsg | Yvc | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jgbfbyk | Skgnbq | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wsjyrskqn | Qhdtpw | $97.8 Bil | |
MRNA
| Moderna Inc | Vvspbqwt | Bfvk | $41.3 Bil | |
ARGX
| argenx SE ADR | Klcyyrvn | Bsxy | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Drwzmsyn | Fmvyy | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sdjxncm | Wbkwxh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dncvklzzg | Xplsz | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hqkkmggqg | Lbwbsh | $12.5 Bil | |
INCY
| Incyte Corp | Vnnmmgk | Tlvrzn | $11.6 Bil |